180 related articles for article (PubMed ID: 30517530)
21. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
Shanehsaz SM; Ishkhanian S
Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
[TBL] [Abstract][Full Text] [Related]
25. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
[TBL] [Abstract][Full Text] [Related]
26. The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Tayyebi M; Darchini-Maragheh E; Layegh P; Kiafar B; Goyonlo VM
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009241. PubMed ID: 33739976
[TBL] [Abstract][Full Text] [Related]
27. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
Silva RE; Toledo A; Senna MC; Rabello A; Cota G
Mem Inst Oswaldo Cruz; 2016 Aug; 111(8):512-6. PubMed ID: 27508321
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory effects of topical diphencyprone for the treatment of acute urban cutaneous leishmaniasis.
Nahidi Y; Mashayekhi Goyonlo V; Layegh P; Taghavi F; Najaf Najafi M
J Dermatolog Treat; 2021 Mar; 32(2):220-226. PubMed ID: 31294619
[TBL] [Abstract][Full Text] [Related]
29. Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil.
Guimarães LH; Machado PR; Lago EL; Morgan DJ; Schriefer A; Bacellar O; Carvalho EM
Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):712-5. PubMed ID: 19481233
[TBL] [Abstract][Full Text] [Related]
30. Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
Ribeiro MN; Pimentel MI; Schubach Ade O; Oliveira Rde V; Teixeira JL; Leite MP; Fonseca M; Santos GP; Salgueiro MM; Ferreira e Vasconcellos Ede C; Lyra MR; Saheki MN; Valete-Rosalino CM
Rev Inst Med Trop Sao Paulo; 2014; 56(4):291-6. PubMed ID: 25076428
[TBL] [Abstract][Full Text] [Related]
31. Clinical features of cutaneous and disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Paraty, Rio de Janeiro.
Vieira-Gonçalves R; Pirmez C; Jorge ME; Souza WJ; Oliveira MP; Rutowitsch MS; Da-Cruz AM
Int J Dermatol; 2008 Sep; 47(9):926-32. PubMed ID: 18937655
[TBL] [Abstract][Full Text] [Related]
32. Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series.
Serbate Borges Portela Á; Margotto Bertollo C; da Silva Praxedes MF; Silva Brasileiro SA; Moreira Reis AM; Parreiras Martins MA
J Clin Pharm Ther; 2020 Jun; 45(3):573-576. PubMed ID: 31793023
[TBL] [Abstract][Full Text] [Related]
33. Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation.
Aragão Horoiwa T; Cortez M; Sauter IP; Migotto A; Bandeira CL; Cerize NNP; de Oliveira AM
Eur J Pharm Sci; 2020 Apr; 147():105295. PubMed ID: 32145429
[TBL] [Abstract][Full Text] [Related]
34. Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis.
Antonio Lde F; Fagundes A; Oliveira RV; Pinto PG; Bedoya-Pacheco SJ; Vasconcellos Ede C; Valete-Rosalino MC; Lyra MR; Passos SR; Pimentel MI; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(5):375-80. PubMed ID: 25229216
[TBL] [Abstract][Full Text] [Related]
35. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
36. [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis].
Correia D; Macêdo VO; Carvalho EM; Barral A; Magalhães AV; de Abreu MV; Orge ML; Marsden P
Rev Soc Bras Med Trop; 1996; 29(5):447-53. PubMed ID: 8966308
[TBL] [Abstract][Full Text] [Related]
37. Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.
Suprien C; Rocha PN; Teixeira M; Carvalho LP; Guimarães LH; Bonvoisin T; Machado PRL; Carvalho EM
Am J Trop Med Hyg; 2020 Apr; 102(4):777-781. PubMed ID: 32043440
[TBL] [Abstract][Full Text] [Related]
38. Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil.
Toledo Junior A; Daher AB; Amaral TA; Carvalho SF; Romero GA; Rabello A
Rev Soc Bras Med Trop; 2014; 47(6):756-62. PubMed ID: 25626655
[TBL] [Abstract][Full Text] [Related]
39. Intralesional Infiltration with Meglumine Antimoniate for the Treatment of Leishmaniasis Recidiva Cutis in Ecuador.
Calvopiña M; Cevallos W; Paredes Y; Puebla E; Flores J; Loor R; Padilla J
Am J Trop Med Hyg; 2017 Nov; 97(5):1508-1512. PubMed ID: 29016328
[TBL] [Abstract][Full Text] [Related]
40. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
Ramalho DB; Silva RED; Senna MCR; Moreira HSA; Pedras MJ; Avelar DM; Saraiva L; Rabello A; Cota G
Mem Inst Oswaldo Cruz; 2018 Jun; 113(9):e180200. PubMed ID: 29947651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
